Novo Nordisk A/S
Research Novo Nordisk A/S (NOVO-B) on Bullrun: market cap DKK 1.12T, P/E 9.6, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNOVO-B
- ExchangeCO
- CountryDenmark
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyDKK
- Market capDKK 1.12T
- P/E9.6
- Dividend yield3.1%
- Financial periodQ2 2026
- RevenueDKK 78.49B
- Net incomeDKK 20.99B
- Free cash flowDKK 42.40B
- Gross margin78.2%
Valuation Snapshot
latest market cap is DKK 1.12T; P/E is 9.6; dividend yield is 3.1%.
Peer valuation comparison
Latest P/E is 9.63x versus a Healthcare sector median of 24.64x (60.9% below).
Latest dividend yield is 3.1% versus a Healthcare sector median of 1.83% (69.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 309.06B | DKK 102.43B | DKK 58.96B | 81.0% | 23.03 | DKK 26.46B | DKK 119.17B | DKK 203.07B |
| FY2024 | DKK 290.40B | DKK 100.99B | DKK 73.80B | 84.7% | 22.63 | DKK 15.66B | DKK 89.67B | DKK 143.49B |
| FY2023 | DKK 232.26B | DKK 83.68B | DKK 83.10B | 84.6% | 18.62 | DKK 14.39B | DKK 20.53B | DKK 106.56B |
| FY2022 | DKK 176.95B | DKK 55.53B | DKK 66.74B | 83.9% | 12.22 | DKK 12.65B | DKK 24.32B | DKK 83.49B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-25 | DKK 1.12T | 9.6 | 4.6% | 11.7 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 11.7 DKK, yield 3.1%.
| Year | Dividends/share |
|---|---|
| FY2025 | 11.65 DKK |
| FY2024 | 9.9 DKK |
| FY2023 | 7.08 DKK |
| FY2022 | 5.58 DKK |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
ETFs that hold Novo Nordisk A/S
Novo Nordisk A/S is one of the ten largest holdings of 33 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF | 2.53% | 0.38% |
| Amundi MSCI Europe ESG Selection UCITS ETF Acc | 2.07% | 0.20% |
| iShares MSCI Europe Health Care Sector UCITS ETF | 7.09% | 0.18% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | 8.25% | 0.18% |
| Xtrackers MSCI Europe ESG UCITS ETF 1C | 2.46% | 0.20% |
| Amundi MSCI Nordic UCITS ETF-C | 9.95% | 0.25% |
| Xtrackers MSCI Europe Health Care UCITS ETF 1C | 8.32% | 0.17% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | 7.87% | 0.46% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Novo Nordisk A/S's market cap?
Novo Nordisk A/S's market capitalization is DKK 1.12T.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S's price-to-earnings (P/E) ratio is 9.6.
Does Novo Nordisk A/S pay a dividend?
Novo Nordisk A/S has a dividend yield of 3.1%.
What does Novo Nordisk A/S do?
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.